Hepatitis C and HIV-1 coinfection

Gut

Volumn 51, Issue 4, 2002, Pages 601-608

  Mohsen, Abdul H ^a   Easterbrook, P ^a   Taylor, C B ^b   Norris, S ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA INTERFERON; ANTIBODY; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; FAS ANTIGEN; HEPATITIS ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; INTERFERON; INTERLEUKIN 2; PROTEINASE INHIBITOR; RIBAVIRIN; RIBOZYME; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIBODY SCREENING; CARCINOGENESIS; CLINICAL TRIAL; DISEASE COURSE; DRUG USE; GENOTYPE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IMMUNE RESPONSE; IMMUNOTHERAPY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROPREVALENCE; SEXUAL TRANSMISSION; STEATOSIS; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREGNANCY; PREVALENCE; RISK FACTORS;

EID: 0036786892     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.51.4.601     Document Type: Review

References (126)

1. WHO. Hepatitis C: Global Update. Wkly Epidemiol Rec 1997;72:341-4.
2. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;5:707-13.
3. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997;26:2-10S.
4. Sulkowski MS, Mast EE, Seeff LB, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30(suppl 1):S77-84.
5. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997;15:350:1425-31.
6. Yee TT, Griffioen A, Sabin CA, et al. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000;47:845-51.
7. Klein MB, Lalonde RG, Suissa S. Hepatitis C coinfection is associated with increased morbidity and mortality among HIV-infected patients. 8th Conference on Retroviruses and Opportunistic Infections 2001, abstract 569.
8. Bica I, McGovern BH, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-7.
9. Soriano V, Garcia-Samaniego J, Valencia E, et al. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4.
10. Binfield T, Cent C. Hepatitis C in the EuroSIDA cohort of European HIV-infected patients: prevalence and prognostic value. 12th World AIDS Conference, Geneva, Switzerland, Geneva, Switzerland, 1998: abstract 22261.
11. Negredo E, Domingo P, Sambeat M, et al. Influence of coinfection with hepatitis virus on human immunodeficiency plasma viral load. Arch Med 1999;59:2367-8.
12. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-5.
13. Brinker MD, Wit FWNM, Dillen PMEW, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-902.
14. Hayashi PH, Flynn N, McCurdy SA, et al. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991;33:177-80.
15. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevelance and relationship to patients survival. Hepatology 1994;20:1152-5.
16. Merrick ST, Sepkowitz KA, Boyle BA, et al. Seroprevalence of hepatitis C antibody and hepatitis B surface antigenemia in a large urban HIV clinic. 12th World AIDS Conference, Geneva, Switzerland, 1998: abstract 22263.
17. Vogt RL, Richmond-Crum S, Diwan A. Hepatitis C infection in human immune deficiency virus-positive cohort in Hawaii. J Infect Dis 1997;176:542-3.
18. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998;177:1480-8.
19. Pollard RB. Analogy of human immunodeficiency virus to hepatitis C virus: the human immunodeficiency model. Am J Med 1999;107(suppl):41-4.
20. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999;29:150-4.
21. Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C virus infection in patients infected with human immune deficiency virus. Clin Infect Dis 1993;17:117-9.
22. Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993;81:412-18.
23. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47(RR-19):1.
24. Bonacini M, Lin HJ, Hollinger FB. Prevalence of HCV RNA in HIV-infected patients. J Hepatol 1999;30(suppl 1):135.
25. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001;26:340-4.
26. Chamot E, Hirchel B, Wintsch J, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990;4:1275-7.
27. Soto B, Rodrigo L, Garcia-Bengoechea M, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings. J Intern Med 1994;236:515-19.
28. Green ST, Mohsen AH, McKendrick MW, et al. Potential for hepatitis C transmission among non-needle/syringe sharing Sheffield drug injectors through the sharing of drug preparation paraphernalia. Commun Dis Public Health 2001;4:38-41.
29. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore-an analysis of 309 sex partnerships. J Infect Dis 1995;171:768-75.
30. Craib KJP, Sherlock CH, Hogg RS, et al. Evidence of sexual transmission of hepatitis C virus (HCV) in a cohort of homosexual men. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001: abstract 561.
31. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lancet 1995;345:289-91.
32. Tovo PA, Palomba E, Ferraris G, et al. Increased risk of maternal-infant hepotitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Clin Infect Dis 1997;25:1121-4.
33. Mazza C, Ravaggi A, Rodella A, et al. Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. J Med Virol 1998;54:12-19.
34. Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000;356:904-7.
35. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. Br J Obstet Gynaecol 2001;108:371-7.
36. Lam JPH, McOmish F, Burns SM, et al. Infrequent vertical transmission of hepatitis C virus. J Infect Dis 1993;167:572-6.
37. Paccagnini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995;14:195-9.
38. Zuccotti GV, Ribero ML, Giovannini M, et al. Effect of hepatitis C genotype on mother-to-infant transmission of virus. J Pediatr 1995;127:278-80.
39. Granovsky MO, Minkof HL, Tess BH, et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998;102:355-9.
40. Hershow RC, Riester KA, Lew J, et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C viruscoinfected mothers. J Infect Dis 1997;176:414-20.
41. Ghany MG, Leissinger C, Lagier R, et al. Effect of human immunodeficiency virus infection on hepatitis C virus infection in haemophiliacs. Dig Dis Sci 1996;41:1265-72.
42. Sherman KE, O'Brien J, Gutierrez AG, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infection. J Clin Microbiol 1993;31:2679-82.
43. Eyster ME, Fried MW, Di Bisceglie AM, et al. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to HIV infection and liver disease. Blood 1994;84:1020-3.
44. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131-6.
45. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-5.
46. Dragoni F, Cafolla A, Gentile G, et al. HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Hematologica 1999;84:525-9.
47. Beld M, Penning M, Lukashov V, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998;244:504-12.
48. Bonacini M, Govindarajan S, Blatt LM, et al. Patients coinfected with human immunodeficiency virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999;6:203-8.
49. Yokozaki S, Takamatsu J, Nakano I, et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000;96:4293-9.
50. Daar ES, Lynn H, Donfield S, Gomperts E, et al. Hemophilia Growth and Development Study. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001;26:466-72.
51. Boncini M, Lin HJ, Hollinger B. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001;26:340-4.
52. Causse X, Payen JL, Izopet J, et al. Does HIV influence the response of chronic hepatitis C to interferon treatment? J Hepatol 2000;32:1003-10.
53. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-53.
54. Berger A, Prondzinski MVD, Doerr HW, et al. Hepatitis C viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol 1996;48:339-43.
55. Rey D, Fritsch S, Schmitt C, et al. Quantitation of hepatitis C virus RNA in saliva and serum of patients coinfected with HCV and human immunodeficiency virus. J Med Virol 2001;63:117-19.
56. Makris M, Preston FE, Rosendaal FR, et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996;94:746-52.
57. Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998;29:12-19.
58. Lesens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive haemophililiacs and should be treated as an opportunistic infection. J Infect Dis 1999;179:1254-8.
59. Benhamou Y, Bochet M, Di Martino, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-8.
60. Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994;88:397-9.
61. Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993;6:602-10.
62. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
63. Bierhoff E, Fischer HP, Willsch E, et al. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch 1997;430:271-7.
64. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001;183:134-7.
65. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol 1997;92:1130-4.
66. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996;91:2563-8.
67. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis c virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
68. Di Bisceglie A. Hepatitis C. Lancet 1998;351:351-5.
69. International Interferon-Hepatocellular Carcinoma Study Group. Effect of interferon on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351:1535-9.
70. El-Serag H, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
71. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-7.
72. Ray RB, Steele R, Meyer K, et al. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997;272:10983-6.
73. Ray RB, Steele R, Meyer K, et al. Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene 1998;208:331-6.
74. García-Samaniego J, Rodríguez M., Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179-83.
75. Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001;183:589-95.
76. Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus coinfection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998;12:381-8.
77. Dorrucci M, Pezzotti P, Phillips AN, et al. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995;172:1503-8.
78. Lasarte JJ, Garcia-Granero M, Lopez A, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998;28:815-22.
79. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-7.
80. Rehermann B, Chisari FV. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 2000;242:299-325.
81. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-82.
82. Mcmichael AJ, Rowland-Jones S. Cellular immune response to HIV. Nature 2001;410:980-7.
83. Graham CS, Koziel MJ. Why should hepatitis C affect immune reconstitution in HIV-1-infected patients? Lancet 2000;356:1865-6.
84. Lai MM. Hepatitis viruses and signal transduction: true to the core? Hepatology 2000;32:427-9.
85. Taya N, Torimoto Y, Shindo M, et al. Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C. Br J Haematol 2000;110:89-97.
86. Gavazzi P, Richallet G, Morand P, et al. Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV. Pathol Biol 1998;46:412-5.
87. Zylberberg H, Chaix ML, Rabian C, et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. J Infect Dis 1998;26:1104-6.
88. Rockstroh JK, Theisen A, Kaiser R, et al. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-coinfected hemophiliacs. AIDS 1998;12:829-30.
89. Garcia-Samaniego J, Bravo R, Castilla J, et al. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. J Hepatol 1998;28:526-7.
90. Gavazzi G, Bouchard O, Leclercq P, et al. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? AIDS Res Hum Retroviruses 2000;20;16:1021-3.
91. Rutschmann OT, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998;177:783-5.
92. Vento S, Garofano T, Renzini C, et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination. AIDS 1998;12:116-17.
93. Ragni MV, Bontempo FA. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999;180:2027-9.
94. Sulkowski M, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
95. Karras A, Rabian C, Zylberberg H, et al. Severe anoxic hepatic necrosis in an HIV-1 hepatitis C virus coinfected patient starting antiretroviral triple combination therapy. AIDS 1998;12:827-9.
96. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998;12:1256.
97. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998;12:1722-4.
98. Rodriguez-Resado R, Garcia-Samaniego J, Soriano V, et al. Hepatotoxicity after introduction of highly active antiretroviral therapy (HAART). Presented at the 12th World AIDS Conference, Geneva, 1998: abstract 12288.
99. Brinkman K, ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
100. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:245-50.
101. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
102. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
103. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
104. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
105. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon- for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992;165:723-6.
106. Mariott E, Navas S, del Romero J, et al. Treatment with recombinant-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993;40:107-11.
107. Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998;26:16-19.
108. Del Pozo MA, Arias JR, Pinilla J, et al. Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: efficacy, tolerance, and response related factors. Hepatogastroenterology 1998;45:1695-701.
109. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999;13:539-46.
110. Soriano V, Bravo R, Garcia-Samaniego J, et al. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. J Infect 1997;35:225-30.
111. Mauss S, Heintges T, Adams O, et al. Treatment of chronic hepatitis C with interferon-alpha in patients infected with the human immunodeficiency virus. Hepatogastroenterology 1995;42:528-34.
112. Vento S, Di Perri G, Cruciani M, et al. Rapid decline of CD+ cells after IFN- treatment in HIV-1 infection. Lancet 1993;341:958-9.
113. Pesce A, Taillan B, Rosenthal E, et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1-infected patients. Lancet 1993;341:1597.
114. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000;47:694-7.
115. Landau A, Batisse D, Duong Van Huyen JP, et al. Efficacy and safely of combination therapy with interferon-2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000;14:839-44.
116. Nasti G, Gennaro GD, Rizzardini G, et al. Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha2b and ribavirin combination therapy. J Acquir Immune Defic Syndr 2001;26:299-300.
117. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280.
118. Kakuda TN, Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1803-4.
119. Hoggard PG, Kewn S, Barry MG, et al. Effects of drugs on 29,39-dideoxy-29,39-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997;41:1231-6.
120. Soriano V, Garcia-Samaniego J, Perz-Olmeda M, et al. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8-11, 2001: abstract 42.
121. Schlaak JF, Zum B, Gerken G, et al. Sustained HCV eradication after interleukin-2 therapy in patients with HIV/HCV coinfection. Association for the Study of Liver Disease Dallas, Texas, 1999:abstract 431A.
122. Boyd AE, Tayler C, Norris S, et al. Liver transplantation and HIV-a case series of 7 patients. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001:abstract 578.
123. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
124. Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:1771.
125. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and-uninfected homosexual men. J Infect Dis 1997;176:1064-7.
126. Roudot-Thoroval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: French survey of 6664 patients. Hepatology 1997;26:485-90.